Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

By J. Despres, A. Golay, L. Sjöström. New England Journal of Medicine, 2005

1,416 citations recorded by the source corpus.

Subfields: Political Science and International Relations

View Paper: https://www.semanticscholar.org/paper/2d2d82ed5b1b7960ca74d6680f749bf4c8f9f075

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Pacher
2. S. Batkai
3. George Kunos
4. G. R. Hajer
5. F. Visseren
6. T. V. van Haeften
7. David B. Graves

Citations in the corpus

• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “Conversely, rimonabant increases adiponectin secretion by adipocytes (Bensaid et al., 2003) and adiponectin plasma levels in obese human subjects (Després et al., 2005), which should lead to increased lipid β-oxidation and thermogenesis in vivo.”
• Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. (2008, background): “receptor blockade in adipocytes results in changes in adipocytes function.(128)”